Skip to main content

Table 3 The efficacy of the treatments in the B16F10 tumor-bearing mice

From: Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma

Groups

TTEa

TGD (%)b

MSTc

ILS (%)d

Buffer

23.5 ± 2.0

–

23.6

–

Naïve lip

26.7 ± 3.4

13.4

27.3

17.4

Lip-V1

33.1 ± 6.2

40.8

32.0

39.1

Lip-V2

26.9 ± 3.9

14.1

26.0

13.0

Lip-V3

27.4 ± 6.0

16.2

26.0

13.0

  1. aTime to reach the end-point
  2. bTumor growth delay (in comparison with the buffer group)
  3. cMedian survival time
  4. dIncrease life span
Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us